Date Closed

August 8, 2024

Lead Office

Québec City

Value

21.00 Million USD

On September 4, 2024 Feldan Therapeutics, biopharmaceutical company, announced that it completed a US$21 million Series B investment round. The funding will be used to complete a study regarding a non-invasive intralesional treatment designed to provide an alternative treatment to surgery and will support the preclinical development of Feldan's therapeutic pipeline.

Feldan, based in Québec City, Québec, is a biopharmaceutical company that specializes in the development of treatments based on intracellular delivery of therapeutics. Feldan's pipeline focuses on diseases affecting skin and lungs.

Genesys is a Canadian venture capital firm exclusively focused on the life sciences industry. Genesys invests in early stage companies that are in high-growth sectors of life sciences.

FTQ is a development capital fund that supports companies through venture and development capital investments based on the belief that impact is created as much by financial as societal returns.

McCarthy Tétrault advised Feldan with a team led by Charles-Antoine Souliere and Alexandre Saulnier-Marceau that included Mireille Trottier, Philippe April, Kim Godbout, Kevin Gao (Business), Marie-Soleil Landry, and Geneviève Favreau (Tax).